We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+24.48%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.93%
AUM
$72.6B
AUM Growth
+$8.69B
(+14%)
Cap. Flow
+$958M
Cap. Flow % of AUM
Cap. Flow %
1.32%
Top 10 Holdings %
Top 10 Hldgs %
12.01%
Holding
3,761
New
548
Increased
1,084
Reduced
1,502
Closed
621
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 2 |
NVIDIA
NVDA
|
+$938M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$639M |
| 4 |
Netflix
NFLX
|
+$598M |
| 5 |
Amazon
AMZN
|
+$575M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.46B |
| 2 |
Sandisk
SNDK
|
+$1.13B |
| 3 |
Apple
AAPL
|
+$426M |
| 4 |
Linde
LIN
|
+$316M |
| 5 |
Vertiv
VRT
|
+$297M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.58% |
| 2 | Healthcare | 14.83% |
| 3 | Consumer Discretionary | 11.24% |
| 4 | Industrials | 10.49% |
| 5 | Communication Services | 8.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3076
PharmaCyte Biotech
PMCB
$3.68M
| $29.2K | ﹤0.01% |
37,987
-18,513
| -33% | -$13.9K |
2023 Q2
12 quarters
|
|
3077
Canopy Growth
CGC
$307M
| $29K | ﹤0.01% |
+30,500
| New | +$32.4K |
2026 Q2
0 quarters
|
|
|
PMI
3078
Picard Medical
PMI
$37.9M
| $28.2K | ﹤0.01% |
+3,448
| New | +$73.3K |
2026 Q2
0 quarters
|
|
3079
Defiance Daily Target 2x Short RKLB ETF
RKLZ
$30.5M
| $27.5K | ﹤0.01% |
+2,180
| New | +$88.9K |
2026 Q2
0 quarters
|
|
3080
Stablecoin Development Corp
SDEV
$41.4M
| $27.4K | ﹤0.01% |
26,142
-56,653
| -68% | -$78.1K |
2026 Q1
1 quarter
|
|
3081
DELISTED
LivePerson
LPSN
| $26.8K | ﹤0.01% |
+14,111
| New | +$33.9K |
2026 Q2
0 quarters
|
|
3082
Stereotaxis
STXS
$101M
| $26.5K | ﹤0.01% |
15,400
-357,200
| -96% | -$670K |
2022 Q1
17 quarters
|
|
3083
TROOPS Inc
TROO
$199M
| $25.8K | ﹤0.01% |
+10,500
| New | +$33.1K |
2026 Q2
0 quarters
|
|
3084
Kandi Technologies Group
KNDI
$37.8M
| $25.8K | ﹤0.01% |
3,610
-3,160
| -47% | -$23.3K |
2022 Q1
17 quarters
|
|
3085
CBAK Energy Technology Ltd
CBAT
$81.6M
| $24.5K | ﹤0.01% |
41,400
+3,400
| +9% | +$2.6K |
2025 Q3
3 quarters
|
|
3086
eHealth
EHTH
$17.7M
| $24.1K | ﹤0.01% |
16,200
-8,900
| -35% | -$14.9K |
2021 Q4
18 quarters
|
|
3087
Singularity Future Technology
SGLY
$2.68M
| $21.9K | ﹤0.01% |
+5,211
| New | +$29.5K |
2026 Q2
0 quarters
|
|
3088
LiveWire
LVWR
$325M
| $21.5K | ﹤0.01% |
+19,197
| New | +$28.9K |
2026 Q2
0 quarters
|
|
3089
CollPlant Biotechnologies
CLGN
$6.73M
| $21.5K | ﹤0.01% |
6,150
+4,470
| +266% | +$17.2K |
2024 Q4
6 quarters
|
|
3090
Scienjoy Holding
SJ
$39.3M
| $21.5K | ﹤0.01% |
27,504
-500
| -2% | -$556 |
2022 Q2
16 quarters
|
|
3091
Research Frontiers
REFR
$19.3M
| $21.2K | ﹤0.01% |
40,789
-27,511
| -40% | -$22.1K |
2023 Q2
12 quarters
|
|
3092
Freightos
CRGO
$41.3M
| $20.1K | ﹤0.01% |
+13,200
| New | +$24.1K |
2026 Q2
0 quarters
|
|
3093
MOGU Inc
MOGU
$15.7M
| $19.8K | ﹤0.01% |
11,857
-1,132
| -9% | -$2.44K |
2019 Q2
28 quarters
|
|
3094
VivoSim Labs
VIVS
$2.3M
| $19.8K | ﹤0.01% |
+18,500
| New | +$24.9K |
2026 Q2
0 quarters
|
|
3095
Rein Therapeutics
RNTX
$50.2M
| $19.8K | ﹤0.01% |
19,000
-5,500
| -22% | -$6.66K |
2025 Q3
3 quarters
|
|
3096
BeyondSpring
BYSI
$20.6M
| $19.1K | ﹤0.01% |
10,900
-200
| -2% | -$323 |
2024 Q2
8 quarters
|
|
3097
SurgePays
SURG
$6.13M
| $18.4K | ﹤0.01% |
50,900
+1,000
| +2% | +$553 |
2024 Q2
8 quarters
|
|
3098
Cardiff Oncology
CRDF
$73.9M
| $18.1K | ﹤0.01% |
13,942
-87,311
| -86% | -$139K |
2026 Q1
1 quarter
|
|
3099
Milestone Scientific
MLSS
$30.4M
| $18.1K | ﹤0.01% |
56,297
-26,200
| -32% | -$9K |
2023 Q2
12 quarters
|
|
3100
Solarmax Technology
SMXT
$22.3M
| $17.5K | ﹤0.01% |
4,174
-616
| -13% | -$3.91K |
2025 Q3
3 quarters
|
|
Similar funds
Jim Simons's Q2 2026 Portfolio in Review
As of Q2 2026, Jim Simons held 3,761 positions worth $72.6B, up 14% from $63.9B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2026 filing shows 548 new, 1,084 increased, 1,502 reduced and 621 closed positions. Its largest new stake was Amazon: 2,290,710 shares worth $546M. The largest sale was Micron Technology, an estimated $1.46B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2026 buy was Amazon: 2,290,710 shares worth $546M.
- Jim Simons added most to Meta Platforms (Facebook) in Q2 2026, an estimated $1.08B increase.
- Jim Simons's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.46B.
- Jim Simons fully exited Applovin in Q2 2026, selling an estimated $174M.
- Jim Simons's ten largest holdings make up 12% of its $72.6B portfolio in Q2 2026.
- Jim Simons opened 548 new positions and closed 621 in Q2 2026.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $72.6B.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.